Highlights from the Week of 24th August 2026 - 31st August 2026 ( US, Launch ) Cycle Pharma launches CAVHANZA in the US to offer dosing flexibility and tolerability for patients with Ph+ CML ( EU, Launch ) Celltrion launches OMLYCLO 300 mg PFS and AI presentations in key European markets for CSU and allergic asthma ( FDA, Approval ) J&J receives approval from the FDA for IMAAVY to treat wAIHA in patients aged 12 and older ( FDA, Approval ) Jazz Pharmaceuticals gets FDA approval for ZIIHERA regimens to treat adults with unresectable locally advanced or metastatic HER2+ gastroesophageal adenocarcinoma Pg 1/5 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 24th August – 31st August in the world of pharma and healthcare!

Uncategorized /

Highlights from the Week of 24th August – 31st August in the world of pharma and healthcare! Read More »